Form 4 for RLMD RELMADA THERAPEUTICS, INC.
Accepted 2025-11-06 00:00:00 ET · period of report 2025-11-05 · accession 0001213900-25-106837 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-06 | 2025-11-05 | RLMD | TRAVERSA SERGIO | CEO, Dir | P - Purchase | $2.20 | +272.5K | 1.27M | +27% | +$599.5K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-11-05 | P | A | 272,500 | $2.20 | 1,272,500 | D | — | — |